3.50
0.29%
+0.010
Aspira Women's Health Inc stock is currently priced at $3.50, with a 24-hour trading volume of 1,117.
It has seen a +0.29% increased in the last 24 hours and a -4.11% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $3.41 pivot point. If it approaches the $3.57 resistance level, significant changes may occur.
Aspira Women's Health Inc Stock (AWH) Financials Data
Aspira Women's Health Inc (AWH) Revenue 2024
AWH reported a revenue (TTM) of $9.15 million for the quarter ending December 31, 2023, a +11.85% rise year-over-year.
Aspira Women's Health Inc (AWH) Net Income 2024
AWH net income (TTM) was -$16.18 million for the quarter ending December 31, 2023, a +45.86% increase year-over-year.
Aspira Women's Health Inc (AWH) Cash Flow 2024
AWH recorded a free cash flow (TTM) of -$15.92 million for the quarter ending December 31, 2023, a +49.14% increase year-over-year.
Aspira Women's Health Inc (AWH) Earnings per Share 2024
AWH earnings per share (TTM) was -$1.76 for the quarter ending December 31, 2023, a +55.33% growth year-over-year.
Aspira Women's Health Inc Stock (AWH) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Merchant Minh Hoang | Secretary & General Counsel |
Dec 06 '23 |
Sale |
3.37 |
980 |
3,303 |
0 |
Hombeck Torsten | Chief Financial Officer |
Sep 08 '23 |
Buy |
4.30 |
2,246 |
9,658 |
3,000 |
SCHULER JACK W | 10% Owner |
Jul 24 '23 |
Buy |
2.75 |
181,800 |
499,950 |
1,883,656 |
Sandford Nicole | President & CEO |
Jul 24 '23 |
Buy |
3.98 |
12,563 |
50,001 |
134,665 |
Herchuk Jannie Prestridge | Director |
Jul 24 '23 |
Buy |
3.98 |
8,794 |
35,000 |
23,833 |
Parnell Winfred | Director |
Jul 24 '23 |
Buy |
3.98 |
6,281 |
24,998 |
31,513 |
Cavanaugh Stefanie L. | Director |
Jul 24 '23 |
Buy |
3.98 |
6,281 |
24,998 |
34,904 |
Jordan Veronica GH | Director |
Jul 24 '23 |
Buy |
3.98 |
3,769 |
15,001 |
34,575 |
Vos Ellen O'Connor | Director |
Jul 24 '23 |
Buy |
3.98 |
3,769 |
15,001 |
32,878 |
Merchant Minh Hoang | General counsel and secretary |
Jul 24 '23 |
Buy |
3.98 |
754 |
3,001 |
3,865 |
Aspira Women's Health Inc Stock (AWH) Latest News
Aspira Women’s Health Announces Anthem Blue Cross to Provide Coverage for OvaSuite(SM) in California
GlobeNewswire Inc.
Aspira Women’s Health to Present at the MedInvest Biotech & Pharma Investor Conference
GlobeNewswire Inc.
Aspira Women’s Health to Announce Fourth Quarter and 2023 Year End Earnings Results and Host a Conference Call on Thursday, March 28, 2024
GlobeNewswire Inc.
Masimo (MASI) Beats Q4 Earnings and Revenue Estimates
Zacks Investment Research
Aspira Women’s Health to Participate in Corporate Access Events During JP Morgan Healthcare Conference Week 2024
GlobeNewswire Inc.
$1.7M Bet On Erasca? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
Benzinga
About Aspira Women's Health Inc
Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, the company operates Aspira Synergy, a testing platform and cloud service for decentralized access of protein biomarker and hereditary genetic testing; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, its pipeline products include OVAWatch, EndoCheck, and OVAInherit. The company serves physicians, physician office laboratories, and national and regional laboratories. It has a collaborative research agreement with Baylor Genetics; an agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is headquartered in Austin, Texas.
Cap:
|
Volume (24h):